Amryt Pharma PLC operates as a biopharmaceutical company. The Company develops and delivers treatments for rare and orphan diseases. Amryt Pharma serves customers worldwide.
Company profile
Ticker
AMYT
Exchange
Website
CEO
Joseph Wiley
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Amryt Pharma Holdings Ltd
SEC CIK
AMYT stock data
Latest filings (excl ownership)
15F-12B
Securities registration termination (foreign)
24 Apr 23
EFFECT
Notice of effectiveness
24 Apr 23
EFFECT
Notice of effectiveness
24 Apr 23
EFFECT
Notice of effectiveness
24 Apr 23
POS AM
Prospectus update (post-effective amendment)
18 Apr 23
POS AM
Prospectus update (post-effective amendment)
18 Apr 23
POS AM
Prospectus update (post-effective amendment)
18 Apr 23
6-K
Current report (foreign)
12 Apr 23
25-NSE
Exchange delisting
12 Apr 23
6-K
High Court of Justice of England and Wales Sanctions Scheme of Arrangement
3 Apr 23
Latest ownership filings
SC 13G/A
Athyrium Opportunities III Acquisition 2 LP
18 Apr 23
SC 13G/A
Stonepine Capital Management, LLC
13 Feb 23
SC 13G/A
Rubric Capital Management LP
10 Feb 23
SC 13G/A
HIGHBRIDGE CAPITAL MANAGEMENT LLC
10 Feb 23
SC 13G/A
UBS OCONNOR LLC
14 Feb 22
SC 13G
Rubric Capital Management LP
14 Feb 22
SC 13G/A
Stonepine Capital Management, LLC
11 Feb 22
SC 13G/A
HIGHBRIDGE CAPITAL MANAGEMENT LLC
11 Feb 22
SC 13G/A
EdgePoint Investment Group Inc.
11 Feb 22
SC 13G
EdgePoint Investment Group Inc.
5 May 21
Financial summary
Quarter (USD) | Dec 21 | Dec 20 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |